According to Zacks, “Avantor Inc. is a provider of critical products and services primarily to biopharma, healthcare, education & government, advanced technologies & applied materials industries. Avantor Inc. is based in Radnor, United States. “
Several other equities analysts have also commented on the stock. Cowen lowered their price objective on shares of Avantor from $50.00 to $44.00 in a research report on Tuesday, April 19th. Cowen lowered their target price on shares of Avantor from $50.00 to $44.00 in a report on Tuesday, April 19th. Wells Fargo & Company lowered their target price on shares of Avantor from $42.00 to $33.00 and set an overweight rating for the company in a report on Monday, April 25th. Morgan Stanley lowered their target price on shares of Avantor from $46.00 to $43.00 and set an overweight rating for the company in a report on Monday, February 7th. Finally, Raymond James lowered their target price on shares of Avantor from $43.00 to $40.00 and set an outperform rating for the company in a report on Monday, April 18th. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Avantor presently has an average rating of Buy and an average price target of $43.13.
AVTR stock opened at $31.59 on Tuesday. Avantor has a 52 week low of $28.64 and a 52 week high of $44.37. The company has a quick ratio of 1.11, a current ratio of 1.71 and a debt-to-equity ratio of 2.19. The company has a fifty day simple moving average of $32.92 and a two-hundred day simple moving average of $36.42. The firm has a market capitalization of $19.27 billion, a P/E ratio of 35.49, a price-to-earnings-growth ratio of 0.69 and a beta of 1.53.
Avantor (NYSE:AVTR – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.02. Avantor had a net margin of 7.72% and a return on equity of 33.91%. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the business earned $0.35 earnings per share. Avantor’s quarterly revenue was up 9.2% compared to the same quarter last year. As a group, analysts anticipate that Avantor will post 1.5 EPS for the current year.
In other Avantor news, EVP Gerard Brophy sold 2,027 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $34.47, for a total transaction of $69,870.69. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of AVTR. Morgan Stanley increased its position in Avantor by 3.6% during the 2nd quarter. Morgan Stanley now owns 601,239 shares of the company’s stock valued at $21,350,000 after purchasing an additional 21,118 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Avantor by 15.2% in the 3rd quarter. Janney Montgomery Scott LLC now owns 7,502 shares of the company’s stock worth $307,000 after buying an additional 992 shares during the last quarter. Advisor Group Holdings Inc. grew its position in shares of Avantor by 20.2% in the 3rd quarter. Advisor Group Holdings Inc. now owns 53,742 shares of the company’s stock worth $2,197,000 after buying an additional 9,050 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of Avantor by 13.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 27,321 shares of the company’s stock worth $1,117,000 after buying an additional 3,321 shares during the last quarter. Finally, Duality Advisers LP purchased a new position in shares of Avantor in the 3rd quarter worth approximately $1,015,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.
Avantor Company Profile (Get Rating)
Avantor, Inc provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
Receive News & Ratings for Avantor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Avantor and related companies with MarketBeat.com’s FREE daily email newsletter.